Company to deliver three oral and three poster presentations highlighting its portfolio of non-viral genetic medicines Presentations to include new pre-clinical data on lead non-viral candidates P-KLKB1-101 and P-FVIII-101 SAN DIEGO , April 18, 2024 /PRNewswire/ — Poseida Therapeutics, Inc.